Recursion Pharmaceuticals (RXRX) said Sunday early results from a phase 1/2 trial of its drug REC-4881 for Familial Adenomatous Polyposis showed a median reduction in polyp burden of 43% after 13 weeks among six patients who were evaluated.
The company said five patients saw polyp reductions between 31% and 82%, while one experienced a sharp increase compared to 20% to 30% reductions in other drugs over six months.
Three patients also showed improvement in the Spigelman stage, while one worsened and two had mixed or unclear results.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。